Sources

4 Total Sources

Axiom Biosciences Targets 2027 Hong Kong IPO as Hang Seng Biotech Index Jumps 75%

Left100%
CNBC62d ago
Axiom Biosciences Plans 2027 Hong Kong IPO Before 2029 U.S. Listing
South China Morning Post62d ago
US biotech firm developing therapies for infant brain injuries plans Hong Kong listing | South China Morning Post
Bloomberg62d ago
Axiom Seeks Hong Kong IPO to Tap China's Biotech Boom - Bloomberg
Post Magazine62d ago
US biotech firm developing therapies for infant brain injuries plans Hong Kong listing | South China Morning Post